Endocan and Lumican in Relation to Cardiometabolic Risk in a Pediatric Overweight and Obese Cohort: A Cross-Sectional Study

Table 2

Overweight and obese patient biochemical characteristics.

Variable	patients
Total cholesterol (mg/dL)	166 (49)
LDL cholesterol (mg/dL)	101 (38)
HDL cholesterol (mg/dL)	43.5 (19)
Triglyceride (mg/dL)	92 (70)
Non-HDL cholesterol (mg/dL)	122.5 (44)
Triglyceride/HDL cholesterol ratio	2.04 (2.23)
C-reactive protein (mg/dL)	0.34 (0.79)
Fasting glucose (mg/dL)	88.5 (10)
ASAT (UI/L)	23 (7)
ALAT (UI/L)	29 (14)
Alkaline phosphatase (UI/L)	239 (127)
Uric acid (mg/dL)	4.8 (2.4)
Obese (, %)	59 (86.9%)
Insulin (mU/L)	10.3 (14.26)
HOMA-IR	2.20 (2.87)
Endocan (ng/mL)	2.65 (1.88)
Lumican (ng/mL)	11.75 (6.65)
Hypertension (, %)	32 (47.1%)
Systolic blood pressure percentile	50^th (44)
Diastolic blood pressure percentile	50^th (45)

Data are presented as median (interquartile range). ALAT: alanine aminotransferase; ASAT: aspartate aminotransferase; HDL: high-density lipoprotein; LDL: low-density lipoprotein; HOMA-IR: Homeostatic Model Assessment of Insulin Resistance.